Laboratory developed test

Laboratory developed tests (LDTs) are a type of in vitro diagnostic test that are designed, manufactured, and used within a single laboratory. LDTs are also known as in-house or home-brew tests. These tests are developed by high-complexity laboratories to fill gaps in clinical testing needs that are not met by FDA-approved commercial tests. LDTs can range from simple tests that measure a single analyte to complex genetic panels and algorithms that predict disease risk or therapeutic response.

Overview

LDTs have become increasingly important in the personalized medicine field, particularly for the detection of rare conditions, complex diseases such as cancer, and for the assessment of individual responses to specific therapies. Unlike commercially available tests, LDTs do not require premarket approval by the U.S. Food and Drug Administration (FDA). However, laboratories that develop and use these tests must be certified under the Clinical Laboratory Improvement Amendments (CLIA) to ensure quality laboratory testing.

Regulation

The regulatory landscape for LDTs has been a topic of debate. Historically, the FDA exercised enforcement discretion over LDTs, meaning they did not actively regulate these tests. However, with the advent of more complex tests and their increasing use in critical clinical decision-making, there have been calls for more stringent oversight. The FDA has proposed a risk-based framework for regulating LDTs, focusing on tests that have the highest risk to patients if they fail to perform accurately.

Development and Use

Developing an LDT requires a deep understanding of the disease or condition being tested, as well as expertise in assay development and validation. The process involves selecting appropriate analytes or markers, developing the assay protocol, and rigorously validating the test to ensure its accuracy, precision, and clinical utility.

LDTs are used in various clinical settings, including oncology, genetics, infectious diseases, and pharmacogenomics. In oncology, for example, LDTs can help identify specific mutations in a patient's tumor that can guide targeted therapy decisions. In genetics, LDTs can detect rare genetic disorders that may not be covered by commercial tests.

Challenges and Considerations

One of the main challenges associated with LDTs is ensuring their quality and reliability. Because LDTs are not subject to the same premarket review as FDA-approved tests, there is concern about the potential for variability in test performance across different laboratories. To address this, laboratories must adhere to strict quality control and validation standards under CLIA.

Another consideration is the ethical and legal implications of LDTs, particularly in the context of genetic testing. Issues such as patient consent, privacy, and the potential for genetic discrimination are important considerations for laboratories developing and offering these tests.

Future Directions

The field of LDTs is evolving rapidly, driven by advances in genomics, proteomics, and bioinformatics. Future developments in LDTs are likely to focus on increasing the accuracy, reliability, and clinical relevance of these tests, as well as expanding their use in personalized medicine. Additionally, the regulatory framework for LDTs may continue to evolve to ensure patient safety while fostering innovation in laboratory medicine.